Ipsen (LTS:0MH6) Accounts Payable & Accrued Expense : €882 Mil (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Ipsen Accounts Payable & Accrued Expense?

Ipsen's quarterly accounts payable & accrued expense increased from Dec. 2022 (€710 Mil) to Jun. 2023 (€878 Mil) and increased from Jun. 2023 (€878 Mil) to Dec. 2023 (€882 Mil).

Ipsen's annual accounts payable & accrued expense increased from Dec. 2021 (€661 Mil) to Dec. 2022 (€710 Mil) and increased from Dec. 2022 (€710 Mil) to Dec. 2023 (€882 Mil).

Ipsen Accounts Payable & Accrued Expense Historical Data

The historical data trend for Ipsen's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipsen Accounts Payable & Accrued Expense Chart

Ipsen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

561.70

541.80

660.70

710.40

882.40

Ipsen Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															660.70	643.60	710.40	878.20	882.40

Ipsen Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Ipsen (LTS:0MH6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (LTS:0MH6) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

IPSEY:USA IPSEF:USA IPN:France I7G:Germany

Address

65 Quai Georges Gorse, Billancourt Cedex, Boulogne, FRA, 92100

Website

https://www.ipsen.com

Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.

Ipsen (LTS:0MH6) Headlines

No Headlines